

Immunization Administration Record

Respiratory Syncytial Virus Vaccine (RSV)

Abrysvo or Arexvy

						ADIYS	VO OI AICAVY
First Name:		Last Name:					
Birthdate: Age:		Weight:	Sex assigned	ssigned at birth: Male Female			
Address:		City:	State	State: Zip:			
Phone:			Last 4 digits of Social Security Number:				
	ary Care Physician (PCP) Fire	st Name:	F	PCP Last Name:			
PCP A	Address:						
PCP P	hone:		PCP Fax:				
Indi	cations: Please check "yes"	or "no" for each au	uestion		Yes	No	Notes
1.	Are you 60 years of age of				103	110	110103
2.			n+2				
	For women: Are you 32 t						
3.	Have you previously rece		• •				
	autions and Contraindicat	ions: Please check	"yes" or "no" for each	question.	Yes	No	Notes
4.	Are you sick today?			/-			
5.	Do you have allergies to POLYSORBATE 80), or late		a vaccine component ((EX:			
6.	Have you ever had a serie	ous reaction after r	eceiving a vaccine?				
7.	For women: Are you nurs	sing?					
8.	Have you ever felt dizzy o	or faint before, duri	ng, or after a shot?				
9.	Are you anxious about ge	etting a shot today?					
Talk to	the pharmacist before receiving	g this vaccine to review	the above questions.			l l	
	<u>Cons</u>	sent for services, me	dical records, and HIPAA	A privacy information			
or serv to dete All Pati insurar questic the leg and ow with, o aforem	are/Medigap Policy Holders: I request and ices furnished by them to me. I authorize the termine benefits payable for these or relate ents: I acknowledge receipt of Giant Eaglice provider(s). For the vaccine(s) indicate ones and that I voluntarily assume full responal guardian. I, for myself, my wards, heirs, where, the event sponsors, and each entity in any way related to, the receipt or admitted parties, to any extent whatsoevition with or as a result of their offering of	he release of medical informat d services. e's Notice of Privacy Practices d hereon, I acknowledge recei insibility for any reactions that executors, personal represen e's respective affiliates, subsid inistration of the immunizatio er, liable, responsible, or in ar	and authorize the release of immupt of the relevant Vaccine Informamay result. I request administratio tatives and assigns, hereby release laries, divisions, directors, contract n(s) indicated hereon. Further, I ally way accountable for any loss, physical process, physical process.	edicare and Medicaid Services, unization information to Federation Sheet (VIS) or EUA Fact Shot of the immunization(s) to mee Giant Eagle, Inc., the hosting cors, agents and employees, friffirm that I request and accessingsical or personal injury, death	my Mediga al and state eet. I affirm e or to the facility and om any and these servi n, or dama	e authorities and that I have ho patient identification and all claims arces at my own ges suffered of	In their agents as necessar and to any covering healt had the opportunity to as fied hereon for whom I ar and operating companie sising out of, in connection her sustained at any time i
	l: I agree to be res						this vaccination.
Signa	ture (Patient or Parent/Leg	gal Guardian):					
Drint	Print Full Legal Name (Patient or Parent/Legal Guardian):						

Last reviewed: 6/25/24 CG



Immunization Administration Record

Respiratory Syncytial Virus Vaccine (RSV)

Abrysvo or Arexvy

Healthcare Provider Only

Patient Name:	OB:						
By signing below, I agree that as the immunizing healthcare professional: I reviewed the patient's information and screening question responses. This vaccine is appropriate for this patient based on the responses to the screening questions and age guidelines according to ACIP recommendations, Giant Eagle's current vaccine protocols, and state regulations. Appropriate written education has been provided to the patient, including a Well Child Visit Reminder as applicable.							
Signature (Immunizer): Da	ate:						
Print Name (Immunizer):Title	tle (Immunizer):						
If Pharmacy Intern or Technician, overseeing Pharmacist to sign and print name: _							
If using Immunization Protocol, Ordering Physician name:							
Vaccine: □ Abrysvo (0.5 mL) I.M. Mfgr: Pfizer	Lot Number:						
□ Arexvy (0.5 mL) I.M. Mfgr: GlaxoSmithKline	Expiration Date:						
	VIS Date:						
Sig: Administer 1 shot intramuscularly into the: Left Deltoid Right Deltoid	No Refills						

Screening Questions Reference

Screening Questions Reference						
Question	Response	Guidance **Depending on federal and/or state specific guidelines**				
1.	Yes	Patients 60-74 years of age who have not previously received a dose of RSV vaccine and who are at increased risk of severe RSV disease: Administer one dose of RSV vaccine Patients at increased risk of RSV include: Chronic cardiovascular disease Chronic lung disease Chronic kidney disease, advanced Diabetes mellitus with end organ damage Severe obesity Immunocompromising conditions Neurologic or neuromuscular conditions Liver disorders Hematologic conditions Frailty Residence in a nursing home or LTC facility Other chronic medical conditions or risk factors that a HCP determines would increase the risk of severe disease Patients 75+ years of age who have not previously received a dose of RSV vaccine: Administer one dose of RSV vaccine				
2.	Yes	Administer one dose of ABRYSVO to patients who are pregnant (32 weeks and zero days'—36 weeks and 6 days' gestation) and who have not previously received a dose of vaccine, using seasonal administration.				
3.	Yes	No further doses of RSV vaccine are recommended at this time.				
4.	Yes	As a precaution with moderate or severe acute illness, all vaccines should be deferred until the illness has improved. Mild illnesses are NOT contraindications to vaccination. Do not defer vaccination if a person is taking antibiotics. Evaluate any reported symptoms that may be due to SARS-CoV-2 infection.				
5.	Yes	DO NOT administer the vaccine to patients with history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including POLYSORBATE 80. Check supplies if latex allergy.				
6.	Yes	Gather information from patient on any serious reactions that occurred following previous vaccinations.				
7.	Yes	It is not known whether ABRYSVO is excreted in human milk. Data are not available to assess the effects of ABRYSVO on the breastfed infant or on milk production/excretion.				
8./9.	Yes	Employ strategies to avoid the risk of injury due to dizziness or fainting, and to help the patient's anxiety.				

Last reviewed: 6/25/24 CG